BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6800179)

  • 1. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet function and its disorders--some aspects from the arachidonic acid metabolism.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1984 Dec; 47(8):1542-55. PubMed ID: 6442514
    [No Abstract]   [Full Text] [Related]  

  • 4. [Defects in the prostaglandin system. VIII. A pathologic thrombocyte population in myeloproliferative syndrome, which forms no thromboxane from exogenous arachidonic acid].
    Sinzinger H; Gisslinger H; Linkesch W; Ludwig H; Flener R; Peskar BA
    Wien Klin Wochenschr; 1988 Nov; 100(21):715-8. PubMed ID: 3149432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered arachidonate metabolism by leukocytes and platelets in myeloproliferative disorders.
    Takayama H; Okuma M; Kanaji K; Sugiyama T; Sensaki S; Uchino H
    Prostaglandins Leukot Med; 1983 Nov; 12(3):261-72. PubMed ID: 6318227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
    Berild D; Hasselbalch H; Knudsen JB
    Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of the morphology and function of the thrombocytes in myeloproliferative diseases].
    Petrov MN; Vashkinel' VK
    Probl Gematol Pereliv Krovi; 1977 May; 22(5):18-23. PubMed ID: 267283
    [No Abstract]   [Full Text] [Related]  

  • 9. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
    Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
    Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 13. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
    Gingold N
    Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
    Viero P; Cortelazzo S; Bassan R; Barbui T
    Thromb Haemost; 1982 Oct; 48(2):125-6. PubMed ID: 6184841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 17. Stainable blood platelet glycogen in various conditions.
    Hermanský F; Hrodek O; Matousová O; Cieslar P
    Acta Univ Carol Med Monogr; 1972; 53():165-71. PubMed ID: 4598518
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnostic considerations in myelofibrosis].
    Dieska D; Gocárová K; Horváth A; Vahancík A
    Bratisl Lek Listy; 1970 Nov; 54(5):637-42. PubMed ID: 5276096
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
    Moliterno AR; Hankins WD; Spivak JL
    N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.